A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers

Back to Search
Print
Bookmark Trial

NCT01298544

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Chengxiang Town Hospital
Longan County, Guangxi, 532700, China
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
4-5 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects who participated in and completed Wyeth study 0887X 101518.

- Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Vaccination with any licensed or investigational pneumococcal vaccine since completion
of Wyeth study 0887X 101518.


- History of culture proven invasive disease caused by S pneumoniae since the completion
of Wyeth study 0887X 101518.


- Known or suspected immune deficiency or suppression since participation in Wyeth study
0887X 101518.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Edegem,
  2. Jindrichuv Hradec,
  3. Jindrichuv Hradec,
  4. Jindrichuv Hradec,
  5. Pardubice,
  6. Praha 3,
  7. Sezemice,
  8. Helsinki,
  9. Kokkola,
  10. Tampere,
  11. Espoo,
  12. Järvenpää,
  13. Oulu,
  14. Pori,
  15. Seinajoki,
  16. Turku,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Fukuoka-City, Fukuoka
  2. Akashi-City, Hyōgo
  3. Kumamoto-shi, Kumamoto
  4. Setagaya-ku, Tokyo
  5. Shinjuku-ku, Tokyo
  6. Suginami-ku, Tokyo
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Walnut Creek, California
  2. Miami, Florida
  3. Meridian, Idaho
  4. Saint Louis, Missouri
  5. Binghamton, New York
  6. Mobile, Alabama
  7. Chandler, Arizona
  8. Phoenix, Arizona
  9. San Diego, California
  10. Coral Gables, Florida
  11. Crystal River, Florida
  12. Hialeah, Florida
  13. Miami, Florida
  14. El Dorado, Kansas
  15. Wichita, Kansas
  16. Wichita, Kansas
  17. New Orleans, Louisiana
  18. Elkridge, Maryland
  19. Rockville, Maryland
  20. Omaha, Nebraska
  21. Las Vegas, Nevada
  22. Las Vegas, Nevada
  23. Charlotte, North Carolina
  24. Greensboro, North Carolina
  25. Hickory, North Carolina
  26. Raleigh, North Carolina
  27. Raleigh, North Carolina
  28. Wilmington, North Carolina
  29. Fargo, North Dakota
  30. Cincinnati, Ohio
  31. Cincinnati, Ohio
  32. Cleveland, Ohio
  33. Franklin, Ohio
  34. Warwick, Rhode Island
  35. Little River, South Carolina
  36. Mount Pleasant, South Carolina
  37. Bristol, Tennessee
  38. Nashville, Tennessee
  39. Austin, Texas
  40. Fort Worth, Texas
  41. Fort Worth, Texas
  42. Houston, Texas
  43. McKinney, Texas
  44. Pearland, Texas
  45. San Antonio, Texas
  46. Tomball, Texas
  47. Tomball, Texas
  48. Draper, Utah
  49. Salt Lake City, Utah
  50. Salt Lake City, Utah
  51. South Jordan, Utah
  52. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
  1. College Park, Georgia
  2. Jackson Heights, New York
  3. Beaumont, Texas
  4. Beaumont, Texas
  5. McAllen, Texas
  6. Cullman, Alabama
  7. Dothan, Alabama
  8. Phoenix, Arizona
  9. Fayetteville, Arkansas
  10. Bell Gardens, California
  11. Bellflower, California
  12. Covina, California
  13. Gardena, California
  14. Hawthorne, California
  15. Los Angeles, California
  16. Ontario, California
  17. Paramount, California
  18. Valencia, California
  19. West Covina, California
  20. Colorado Springs, Colorado
  21. Apopka, Florida
  22. Boynton Beach, Florida
  23. Gainesville, Florida
  24. Gainesville, Florida
  25. Hialeah, Florida
  26. Homestead, Florida
  27. Loxahatchee Groves, Florida
  28. Miami Lakes, Florida
  29. Miami, Florida
  30. Miami, Florida
  31. Tampa, Florida
  32. Chamblee, Georgia
  33. Columbus, Georgia
  34. Columbus, Georgia
  35. Ammon, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Idaho Falls, Idaho
  39. Idaho Falls, Idaho
  40. Idaho Falls, Idaho
  41. Nampa, Idaho
  42. Ankeny, Iowa
  43. Des Moines, Iowa
  44. Des Moines, Iowa
  45. West Des Moines, Iowa
  46. El Dorado, Kansas
  47. Bardstown, Kentucky
  48. Louisville, Kentucky
  49. Baton Rouge, Louisiana
  50. Covington, Louisiana
  51. Haughton, Louisiana
  52. Metairie, Louisiana
  53. Baltimore, Maryland
  54. Frederick, Maryland
  55. Gulfport, Mississippi
  56. Missoula, Montana
  57. Lincoln, Nebraska
  58. Lincoln, Nebraska
  59. Albuquerque, New Mexico
  60. East Setauket, New York
  61. East Setauket, New York
  62. East Syracuse, New York
  63. Liverpool, New York
  64. Stony Brook, New York
  65. Stony Brook, New York
  66. Dayton, Ohio
  67. Dayton, Ohio
  68. Fairfield, Ohio
  69. South Euclid, Ohio
  70. East Norriton, Pennsylvania
  71. Erie, Pennsylvania
  72. Fort Washington, Pennsylvania
  73. Charleston, South Carolina
  74. Cheraw, South Carolina
  75. North Charleston, South Carolina
  76. Bristol, Tennessee
  77. Clarksville, Tennessee
  78. Kingsport, Tennessee
  79. Corpus Christi, Texas
  80. Houston, Texas
  81. Houston, Texas
  82. Longview, Texas
  83. McAllen, Texas
  84. San Antonio, Texas
  85. Kaysville, Utah
  86. Layton, Utah
  87. Murray, Utah
  88. Roy, Utah
  89. Saint George, Utah
  90. Syracuse, Utah
  91. Charlottesville, Virginia
  92. Charlottesville, Virginia
  93. Vancouver, Washington
  94. Guayama,
  95. Trujillo Alto,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers
Official Title  ICMJE A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518
Brief Summary In 2005, Wyeth conducted study 0887X-101518 (NCT00488826) in which Chinese infants received either Prevenar alone (Group 1), Prevenar given with a Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccine (Group 2) or DTaP alone (Group 3). This follow up study (at least 3 years after the last vaccination) will assess the antibody concentrations in children who previously completed Wyeth study 0887X-101518.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Pneumococcal Disease
Intervention  ICMJE Procedure: Blood draw
One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
Study Arms  ICMJE All subjects
Intervention: Procedure: Blood draw
Publications * Li R, Fang KX, Young M Jr, Zhou X, Chen Z, Liang JZ, Giardina PC, Scott DA. Long-term antibody persistence study (3 years after last dose) of the 7-valent pneumococcal conjugate vaccine in young children in China. Vaccine. 2016 Oct 17;34(44):5359-5365. doi: 10.1016/j.vaccine.2016.08.070. Epub 2016 Sep 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 13, 2012)		335
Original Estimated Enrollment  ICMJE
 (submitted: February 16, 2011)		400
Actual Study Completion Date  ICMJE March 2011
Actual Primary Completion Date March 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female subjects who participated in and completed Wyeth study 0887X 101518.
  • Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

Exclusion Criteria:

  • Vaccination with any licensed or investigational pneumococcal vaccine since completion of Wyeth study 0887X 101518.
  • History of culture proven invasive disease caused by S pneumoniae since the completion of Wyeth study 0887X 101518.
  • Known or suspected immune deficiency or suppression since participation in Wyeth study 0887X 101518.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 4 Years to 5 Years   (Child)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01298544
Other Study ID Numbers  ICMJE B1841009
6114A1-4001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP